Herpes zoster risk and burden of disease in immunocompromised populations: a population-based study using health system integrated databases, 2009-2014
BackgroundEstimate the incidence of herpes zoster (HZ), its complications and healthcare utilization rates in adults (>= 18-years-old) with a wide range of immunocompromised (IC) conditions compared to IC-free cohort.MethodA population-based retrospective study using the Valencia healthcare Integ...
| Autores: | , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2020 |
| País: | España |
| Institución: | Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) |
| Repositorio: | r-FISABIO. Repositorio Institucional de Producción Científica |
| OAI Identifier: | oai:fisabio.fundanetsuite.com:p8761 |
| Acceso en línea: | https://fisabio.portalinvestigacion.com/publicaciones/8761 |
| Access Level: | acceso abierto |
| Palabra clave: | Herpes zoster Immunocompromised Epidemiology Population-based study Healthcare utilization Vaccine |
| Sumario: | BackgroundEstimate the incidence of herpes zoster (HZ), its complications and healthcare utilization rates in adults (>= 18-years-old) with a wide range of immunocompromised (IC) conditions compared to IC-free cohort.MethodA population-based retrospective study using the Valencia healthcare Integrated Databases (VID) (2009-2014). HZ and IC were defined using ICD-9 codes in primary care (PC) and hospitalization registers. Incidence rates (IR), risk of HZ, HZ-recurrence, HZ-complications and healthcare utilization rates were estimated in the IC-cohort compared to IC-free.ResultsThe study population consisted of 4,382,590 subjects, of which 578,873 were IC (13%). IR (in 1000 persons-year) of HZ overall, in IC and in IC-free cohort was 5.02, 9.15 and 4.65, respectively. IR of HZ increased with age in both cohorts and it was higher for all IC conditions studied, reaching up to twelvefold in subjects with stem cell transplantation. IC subjects had 51% higher risk of developing HZ, 25% higher HZ-recurrence and the risk of HZ-complications was 2.37 times higher than in IC-free. HZ-related healthcare utilization was higher in the IC-cohort than in IC-free (number of hospitalizations 2.93 times greater, hospital stays 12% longer, 66% more HZ-specialist visits, 2% more PC visits, sick leaves 18% longer and 20% higher antiviral dispensation).ConclusionsPatients suffering from all the IC conditions studied are at higher risk of developing HZ, HZ-recurrence and post-herpetic complications, which implies a substantial morbidity and a high consumption of resources. These results should be considered for vaccine policy implementation. |
|---|